Immunovia AB (publ) reported earnings results for the second quarter and six months ended June 30, 2023. For the second quarter, the company reported sales was SEK 0.412 million compared to SEK 0.103 million a year ago. Revenue was SEK 0.416 million compared to SEK 0.108 million a year ago. Net loss was SEK 170.21 million compared to SEK 33.73 million a year ago. Basic loss per share from continuing operations was SEK 4 compared to SEK 1.49 a year ago. Diluted loss per share from continuing operations was SEK 4 compared to SEK 1.49 a year ago.
For the six months, sales was SEK 0.931 million compared to SEK 0.285 million a year ago. Revenue was SEK 1.01 million compared to SEK 0.309 million a year ago. Net loss was SEK 221.86 million compared to SEK 77.84 million a year ago. Basic loss per share from continuing operations was SEK 6.81 compared to SEK 3.44 a year ago. Diluted loss per share from continuing operations was SEK 6.81 compared to SEK 3.44 a year ago.